Rebecca Crews Talks About Getting New Parkinson’s Disease Treatment

Why It Matters

The treatment demonstrates that non‑invasive focused ultrasound can quickly alleviate motor symptoms, offering a viable option for patients reluctant to undergo surgical DBS. Its FDA‑approved bilateral use could broaden adoption and reshape Parkinson’s care pathways.

Key Takeaways

• Focused ultrasound approved for bilateral Parkinson's treatment in July 2025
• Rebecca Crews reported immediate tremor reduction after first procedure
• Procedure uses MRI‑guided sound waves, no incisions needed
• Second‑side treatment performed six months later, further improving balance
• Ultrasound seen as less invasive alternative to deep brain stimulation

Pulse Analysis

Focused ultrasound has moved from a niche experimental tool to a mainstream therapeutic option for Parkinson’s disease. After the FDA cleared Insightec’s Exablate Neuro for unilateral tremor‑dominant cases in 2018, it broadened its label in 2021 to address rigidity and dyskinesia, and finally authorized staged bilateral procedures in July 2025. The technology leverages high‑frequency sound waves, precisely focused under MRI guidance, to ablate targeted thalamic tissue without scalp incisions. This non‑invasive approach reduces hospital stays and eliminates the hardware risks associated with deep brain stimulation (DBS), positioning it as a compelling alternative for patients and clinicians alike.

Patient stories like Rebecca Crews’s underscore the real‑world impact of the therapy. Crews, diagnosed in 2015, experienced immediate tremor cessation, regained fine‑motor control for writing, and restored single‑leg balance—outcomes she described as “pioneer‑like.” Her rapid recovery, achieved while awake and under mild sedation, highlights the procedure’s tolerability and the psychological boost of seeing tangible improvement. Compared with DBS, which requires implanted electrodes and ongoing programming, focused ultrasound offers a one‑time, incision‑free solution, potentially expanding eligibility to those who are surgical candidates or who fear hardware complications.

The broader industry is taking note. Investors are tracking a surge in focused‑ultrasound startups aiming to combine the modality with emerging therapies, such as stem‑cell delivery, to address the disease’s underlying neurodegeneration. Market analysts project a compound annual growth rate of over 15% through 2035 as reimbursement pathways solidify and clinical data accumulate. Moreover, advocacy groups like the Michael J. Fox Foundation are amplifying awareness, accelerating patient enrollment in trials, and influencing policy. As more high‑profile patients share success stories, focused ultrasound is poised to reshape the Parkinson’s treatment landscape, driving both clinical adoption and innovation pipelines.